We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+5.59%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$169M
AUM Growth
-$13M
(-7.2%)
Cap. Flow
-$17.8M
Cap. Flow
% of AUM
-10.58%
Top 10 Holdings %
Top 10 Hldgs %
6.26%
Holding
495
New
55
Increased
122
Reduced
257
Closed
60
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$947K |
| 2 |
Moderna
MRNA
|
+$899K |
| 3 |
Meta Platforms (Facebook)
META
|
+$895K |
| 4 |
Netflix
NFLX
|
+$876K |
| 5 |
Chipotle Mexican Grill
CMG
|
+$852K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ATVI
Activision Blizzard
ATVI
|
+$1.01M |
| 2 |
Progressive
PGR
|
+$999K |
| 3 |
Stryker
SYK
|
+$984K |
| 4 |
Republic Services
RSG
|
+$973K |
| 5 |
Linde
LIN
|
+$966K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.98% |
| 2 | Technology | 15.96% |
| 3 | Financials | 11.34% |
| 4 | Energy | 8.43% |
| 5 | Industrials | 8.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Biohaven
BHVN
$2.18B
| $107K | 0.06% |
4,460
-1,978
| -31% | -$34K |
|
|
MRTX
352
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $107K | 0.06% |
2,952
+634
| +27% | +$26.1K |
|
|
NUVL
353
DELISTED
Nuvalent
NUVL
| $106K | 0.06% |
2,524
-603
| -19% | -$22.8K |
|
354
ImmunityBio
IBRX
$7.32B
| $105K | 0.06% |
37,888
+22,879
| +152% | +$64.7K |
|
|
FLNA
355
Filana Therapeutics
FLNA
$43.5M
| $105K | 0.06% |
4,293
+2,005
| +88% | +$48.3K |
|
356
AtaiBeckley Inc
ATAI
$2.65B
| $105K | 0.06% |
61,089
+28,450
| +87% | +$52.4K |
|
|
INBX
357
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $105K | 0.06% |
4,044
+606
| +18% | +$14.2K |
|
358
Immatics
IMTX
$1.18B
| $105K | 0.06% |
9,088
-1,382
| -13% | -$12.9K |
|
359
Novavax
NVAX
$1.23B
| $105K | 0.06% |
14,085
+8,212
| +140% | +$64.6K |
|
360
Protagonist Therapeutics
PTGX
$8.72B
| $105K | 0.06% |
3,786
-6,500
| -63% | -$163K |
|
361
Syndax Pharmaceuticals
SNDX
$1.82B
| $104K | 0.06% |
4,983
+863
| +21% | +$18K |
|
|
MORF
362
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $104K | 0.06% |
1,818
-1,864
| -51% | -$97.3K |
|
|
BCYC
363
Bicycle Therapeutics
BCYC
$276M
| $104K | 0.06% |
4,074
+929
| +30% | +$21.6K |
|
364
Vaxcyte
PCVX
$8.01B
| $104K | 0.06% |
2,075
-136
| -6% | -$6.45K |
|
365
CRISPR Therapeutics
CRSP
$4.6B
| $104K | 0.06% |
1,844
-173
| -9% | -$9.82K |
|
|
SWTX
366
DELISTED
SpringWorks Therapeutics
SWTX
| $103K | 0.06% |
3,946
-368
| -9% | -$9.67K |
|
367
Prothena Corp
PRTA
$455M
| $103K | 0.06% |
1,513
-230
| -13% | -$14.8K |
|
|
ITOS
368
DELISTED
iTeos Therapeutics
ITOS
| $103K | 0.06% |
7,773
+2,991
| +63% | +$42.6K |
|
369
IDEAYA Biosciences
IDYA
$3.54B
| $103K | 0.06% |
4,378
-1,594
| -27% | -$32.8K |
|
370
Vir Biotechnology
VIR
$1.48B
| $103K | 0.06% |
4,179
+274
| +7% | +$6.88K |
|
371
Xencor
XNCR
$1.47B
| $102K | 0.06% |
4,097
+552
| +16% | +$15K |
|
|
VTYX
372
DELISTED
Ventyx Biosciences
VTYX
| $102K | 0.06% |
3,103
+123
| +4% | +$4.24K |
|
373
Cytokinetics
CYTK
$10.9B
| $101K | 0.06% |
3,106
+661
| +27% | +$24.5K |
|
374
Arbutus Biopharma
ABUS
$871M
| $101K | 0.06% |
44,024
+6,827
| +18% | +$17.8K |
|
|
CERE
375
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $101K | 0.06% |
3,182
-578
| -15% | -$17.7K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2023 Portfolio in Review
As of Q2 2023, Virtus ETF Advisers held 495 positions worth $169M, down 7.2% from $182M the previous quarter. Its ten largest holdings account for 6.3% of the portfolio.
Virtus ETF Advisers withdrew a net $17.8M in Q2 2023, closing 60 positions and reducing 257 holdings. Its most notable exit was Activision Blizzard, an estimated $1.01M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 26% a quarter earlier, followed by Technology and Financials.
Against the trend, Virtus ETF Advisers opened a new position in NVIDIA worth $1.21M.
- Virtus ETF Advisers's largest Q2 2023 buy was NVIDIA: 28,520 shares worth $1.21M.
- Virtus ETF Advisers added most to Moderna in Q2 2023, an estimated $899K increase.
- Virtus ETF Advisers's biggest Q2 2023 reduction was Dow Inc, cutting an estimated $898K.
- Virtus ETF Advisers fully exited Activision Blizzard in Q2 2023, selling an estimated $1.01M.
- Virtus ETF Advisers's ten largest holdings make up 6.3% of its $169M portfolio in Q2 2023.
- Virtus ETF Advisers opened 55 new positions and closed 60 in Q2 2023.
- Virtus ETF Advisers's portfolio value fell 7.2% quarter-over-quarter to $169M.
Based on Virtus ETF Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.